ArticleInternational journal of clinical and experimental pathology2017
MicroRNA-641 inhibits lung cancer cells proliferation, metastasis but promotes apoptosis in cells by targeting PDCD4.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- CRNDE: A Pivotal Oncogenic Long Non-Coding RNA in Cancers.The Yale journal of biology and medicine · 2023Review
- MicroRNA-22-3p and MicroRNA-149-5p Inhibit Human Hepatocellular Carcinoma Cell Growth and Metastasis Properties by Regulating Methylenetetrahydrofolate Reductase.Current issues in molecular biology · 2022Article
- Long non-coding RNA LINC00173 enhances cisplatin resistance in hepatocellular carcinoma via the microRNA-641/RAB14 axis.Oncology letters · 2021Article
- Long non-coding RNA LINC01194 promotes the proliferation, migration and invasion of lung adenocarcinoma cells by targeting miR-641/SETD7 axis.Cancer cell international · 2020Article
- lncRNA Colorectal Neoplasia Differentially Expressed (CRNDE) Promotes Proliferation and Inhibits Apoptosis in Non-Small Cell Lung Cancer Cells by Regulating the miR-641/CDK6 Axis.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of microRNAs (miRNAs) are found in various human cancers, but the roles of miR-641 in lung cancer are still unclear. Our purpose is to explore miR-641 effects on the cellular behavior of A549 cells and the related molecular mechanisms. RT-qPCR assay was conducted to examine the expression of miR-641 in lung cancer and normal lung cell lines. A549 cells were transfected with miR-641 mimic and inhibitor, programmed cell death 4 (PDCD4) targeted siRNA and corresponding controls. Then, cell viability, migration, invasion and apoptosis were analyzed by Cell Counting Kit-8 (CCK-8), Transwell and flow cytometry assays. The expression of apoptosis-related factors and epithelial mesenchymal transition (EMT)-related factors were detected by western blot and RT-qPCR. A target gene of miR-641 was validated by dual-luciferase assay. Besides, the main factors expressions of JAK/STAT and PI3K/AKT signal pathways were measured by western blot. Results showed that miR-641 was low expressed in A549, H1650 and H1299 cells compared to WI-38 and HEL-1 cells. MiR-641 overexpression inhibited cell viability, migration, invasion but promoted apoptosis and apoptosis-related factors levels. Moreover, miR-641 overexpression inhibited TGF-β1-induced EMT in A549 cells. Additionally, PDCD4 was a direct target of miR-641 and PDCD4 silencing notably induced apoptosis, and relieved miR-641 suppressing promoted cell viability, migration and invasion. Finally, PDCD4 silencing blocked miR-641 suppression-induced activations of JAK/STAT and PI3K/AKT signal pathways. In conclusion, miR-641 inhibited cell proliferation and metastasis but promoted apoptosis in lung cancer cells by targeting PDCD4 and blocking JAK/STAT and PI3K/AKT signal pathways.
Indexed as
Identifiers
31966672PMC6965428W3003315595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.